Biotechnology
News Category
GeoVax Advances GEO-MVA Vaccine Program Toward Phase 3 Trial with Clinical Product Release
GeoVax completes release testing for GEO-MVA clinical supplies, enabling a pivotal Phase 3 immune bridging study under EMA guidance to address critica...
VolitionRx Reports Over 95% Early-Stage Cancer Detection Using Capture-Seq Technology
VolitionRx announced proof-of-concept data showing over 95% sensitivity for stage I and II cancers using its Capture-Seq liquid biopsy technology, tar...
Redwood AI Launches Chemical Risk Assessment Initiative, Appoints Stanford Chemist as Scientific Advisor
Redwood AI Corp. has initiated a Chemical Risk Assessment Module for its Reactosphere platform and appointed Stanford chemist Dr. Noah Burns as scient...
VERAXA Biotech Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
VERAXA Biotech highlights partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms, backed by new proof-of-concept data, at the upcoming BIO...
Onco-Innovations Limited Announces C$5 Million Private Placement to Advance ONC010 Program
Onco-Innovations has secured C$5 million in private placement funding to advance its ONC010 cancer treatment program and SynoGraph platform.
VERAXA Biotech Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
VERAXA Biotech AG is highlighting its BiTAC-ADC and BiTAC-TCE platforms, which show potential for improving cancer treatment precision and reducing of...
Quantum BioPharma’s Lucid-MS Targets Myelin Repair in Multiple Sclerosis, Advancing to Phase 2 Trials
Quantum BioPharma’s novel drug candidate Lucid-MS, which directly targets myelin repair, is preparing for phase 2 trials, offering a potential shift i...
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
The expansion of DNA Damage Response inhibitors beyond PARP inhibitors, led by companies like Onco-Innovations, AstraZeneca, and Boundless Bio, is dri...
Onco-Innovations Targets Next Wave of DNA Damage Response Cancer Therapies with PNKP Inhibitor
Onco-Innovations is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor, positioning itself as a potential leader in a novel class of cancer ...
NanoViricides Ships NV-387 Oral Gummies to DRC for Phase II MPox Trial
NanoViricides has shipped its broad-spectrum antiviral candidate NV-387 to the Democratic Republic of Congo for a Phase II clinical trial against MPox...
BioUtah Participates in National Symposium on Biotechnology's Role in National Security
BioUtah joined the Biotech Across America State Symposium in Washington, D.C. to discuss how state and local biotech ecosystems strengthen national se...
Soligenix Nears Key Clinical Milestones as Zacks Report Highlights HyBryte and Dusquetide Prospects
Soligenix is approaching critical clinical readouts in 2026, including the Phase 3 FLASH2 trial for HyBryte in CTCL and progress with dusquetide for B...
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming
A landmark Phase III trial shows proton therapy significantly improves survival for oropharyngeal cancer patients, validating LIXTE Biotechnology's st...
Okogen Acquires Ranpirnase Assets, Expanding Antiviral Pipeline Beyond Ophthalmology
Okogen Inc. has acquired the global intellectual property and development assets for ranpirnase from Orgenesis Inc., strengthening its ophthalmic prog...
Lexaria Expands Patent Portfolio with Five New Grants, Including Two for GLP-1 Diabetes Treatments
Lexaria Bioscience Corp. received five new patents, including two for diabetes treatment using its DehydraTECH technology with GLP-1 drugs, strengthen...
Oragenics Reports Going Concern Audit Opinion, Raising Questions About Financial Stability
Oragenics Inc. disclosed a going concern audit opinion for fiscal 2025, highlighting potential financial risks as it advances its lead concussion trea...
Soligenix Receives EU Orphan Drug Designation for Dusquetide in Behçet Disease
Soligenix announced EU orphan drug designation for dusquetide in Behçet disease, providing up to 10 years of market exclusivity and advancing its inna...
Soligenix Reports 2025 Results, Highlights Phase 3 CTCL Progress and Orphan Drug Milestones
Soligenix announced progress in its Phase 3 FLASH2 trial for cutaneous T-cell lymphoma and orphan drug designation for dusquetide in Behçet’s Disease,...
Nutriband Selects Global Brand Name for AVERSA Fentanyl Patch, Targeting Abuse Deterrence
Nutriband announced the selection of a proposed worldwide brand name for its abuse-deterrent fentanyl patch, aiming to be the first such product to re...
Lantern Pharma Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones
Lantern Pharma reports continued progress in its AI-driven oncology pipeline, including the LP-300 Phase 2 HARMONIC trial and planned FDA discussions,...
Annovis Bio Highlights Buntanetap Development in The Scientist Publication
Annovis Bio's lead drug candidate buntanetap, featured in The Scientist, shows promise in Phase 3 trials for Alzheimer's and Parkinson's diseases.
Tonix Pharmaceuticals Reports Positive Phase 1 Data for Lyme Disease Prophylaxis Candidate TNX-4800
Tonix Pharmaceuticals announced Phase 1 results for TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, showing sustained protect...
GeoVax Announces Warrant Inducement Transaction to Raise Approximately $863,000
GeoVax Labs has entered into a warrant inducement agreement with institutional investors to raise gross proceeds of about $863,000 by reducing the exe...
LIXTE Biotechnology Expands LB-100 Clinical Trials Targeting Ovarian and Colon Cancers
LIXTE Biotechnology announces expanded clinical trials for its lead compound LB-100, aiming to address treatment challenges in ovarian clear cell carc...
LIXTE Biotechnology’s LB-100: A Unique PP2A Inhibitor in Clinical Development
LIXTE Biotechnology Holdings holds the world’s only clinical-stage PP2A inhibitor, LB-100, which enhances cancer cell sensitivity to therapies and dis...
Soligenix Expands Rare Disease Pipeline with UK Designation for SGX945
Soligenix's investigational therapy SGX945 receives Promising Innovative Medicine designation in the UK, underscoring its potential and the company's ...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlights Transformational Year
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, detailing a year of leadership changes, clinical progress, acquisition of Liora ...
Lexaria Launches New Human Clinical Study Evaluating DehydraTECH-Semaglutide Tablets and Capsules Against Wegovy®
Lexaria Bioscience has initiated a 5-week human pilot study comparing two oral DehydraTECH-semaglutide formulations to commercial Wegovy® tablets, aim...
LIXTE Biotechnology's LB-100: The World's Only Clinical-Stage PP2A Inhibitor Poised to Transform Cancer Treatment
LIXTE Biotechnology's lead compound LB-100, the only clinical-stage PP2A inhibitor, enhances cancer cell sensitivity to therapy and disrupts DNA repai...
Soligenix Advances Phase 3 CTCL Trial and Orphan Drug Programs in 2025 Results
Soligenix reported 2025 results highlighting progress in its rare disease pipeline, including the Phase 3 FLASH2 trial for cutaneous T-cell lymphoma a...
Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE
Sigyn Therapeutics is launching a collaborative initiative to evaluate emerging medical technologies, including its CardioDialysis blood purification ...
NurExone Biologic Wins BOLD Awards VII Healthcare Honor, Engages IBN for Investor Outreach
NurExone Biologic's first-place win in the BOLD Awards VII Healthcare category underscores its leadership in exosome-based therapies for CNS injuries,...
Lantern Pharma to Host Investor Briefing with Live Demo of withZeta.ai Platform
Lantern Pharma announces an investor briefing on April 9, 2026, featuring a live demonstration of its withZeta.ai platform, highlighting its potential...
Oncotelic Therapeutics Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform
Oncotelic Therapeutics has partnered with TechForce Robotics to commercialize an AI-driven, GMP-compliant robotics platform for pharmaceutical manufac...
Biotech Labz Supply Inc. Strengthens Position as Trusted Research Peptide Supplier with Documentation and Quality Focus
Biotech Labz Supply Inc. emphasizes its commitment to quality, documentation, and controlled distribution for research-use-only peptides, positioning ...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlights Transformational Year with Clinical and Strategic Advances
LIXTE Biotechnology Holdings filed its 2025 annual report, detailing leadership changes, expanded clinical trials for its lead compound LB-100, the ac...
OMRON Healthcare and UCSF Launch Randomized Controlled Trial for Early AFib Detection via Home Blood Pressure Monitoring
OMRON Healthcare and UCSF have initiated a randomized controlled trial to evaluate whether home blood pressure monitors with AFib detection can improv...
MindBio Therapeutics Targets South American Mining Sector with Voice-Based Impairment Detection Platform as Commercial Deployment Nears
MindBio Therapeutics is preparing to deploy its AI-powered voice analysis technology for drug and alcohol impairment detection in industrial settings,...
TransCode Therapeutics Secures Up to $20 Million Financing Agreement to Advance Phase 2a Trial
TransCode Therapeutics (NASDAQ: RNAZ) entered a financing agreement for up to $20 million with an institutional healthcare investor to support its Pha...
NanoViricides Files for Rare Pediatric Disease Designation for Measles Drug Candidate NV-387
NanoViricides has filed for Rare Pediatric Disease Drug designation for NV-387 as a measles treatment, potentially qualifying for a Priority Review Vo...
BioStem Technologies to Present Expanded Product Portfolio and Clinical Data at SAWC Spring 2026
BioStem Technologies will showcase its new Neox product line and clinical evidence at the Symposium on Advanced Wound Care, highlighting its commitmen...
Synbio International Achieves DWAC and DRS Eligibility, Enhancing Trading Efficiency and Shareholder Access
Synbio International Inc. has been approved for DWAC and DRS processing, modernizing its trading infrastructure to enable faster electronic transfers ...
Oncotelic Therapeutics Featured in AINewsWire Editorial Highlighting AI's Role in Pharma Compliance
Oncotelic Therapeutics is featured in an AINewsWire editorial discussing how AI is transforming pharmaceutical manufacturing and regulatory compliance...
Kraig Biocraft Laboratories Sets World Record with 1.3 Metric Tons of Spider Silk Production in One Month
Kraig Biocraft Laboratories achieves a record 1.3 metric tons of recombinant spider silk cocoons in a month, signaling progress toward industrial-scal...
Oncotelic Therapeutics Featured in Editorial on AI-Driven Pharma Manufacturing
Oncotelic Therapeutics is highlighted in an AINewsWire editorial discussing the integration of AI into pharmaceutical manufacturing as a continuous co...
Annovis Bio Closes $10 Million Offering to Fund Phase 3 Milestones Through 2027
Annovis Bio raised $10 million via an underwritten public offering, extending cash runway to Q2 2027 and supporting Phase 3 Alzheimer's trial data rea...
Blocking RNA Removal Could Enhance Immunotherapy Against Cancer
A study reveals that inhibiting the natural mechanism that removes faulty RNA from cancer cells may boost immune system detection and immunotherapy ef...
Oragenics Doses First Patient in Phase IIa Trial of Concussion Treatment ONP-002
Oragenics has dosed the first patient in its Phase IIa trial of ONP-002 for concussion, targeting a large unmet need with no FDA-approved pharmacologi...